Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy

Mineralocorticoid receptor antagonists (MRAs) slow cardiomyopathy in patients with Duchenne muscular dystrophy (DMD) and improve skeletal muscle pathology and function in dystrophic mice. However, glucocorticoids, known antiinflammatory drugs, remain a standard of care for DMD, despite substantial s...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Zachary M., Gomatam, Chetan K., Rabolli, Charles P., Lowe, Jeovanna, Piepho, Arden B., Bansal, Shyam S., Accornero, Federica, Rafael-Fortney, Jill A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675571/
https://www.ncbi.nlm.nih.gov/pubmed/36040807
http://dx.doi.org/10.1172/jci.insight.159875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675571/
https://www.ncbi.nlm.nih.gov/pubmed/36040807
http://dx.doi.org/10.1172/jci.insight.159875

Ejemplares similares